Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ImpediMed - AstraZeneca extends and increases HF & Renal Contract (ASX:IPD)

Key Highlights AstraZeneca extends its contract for the Phase IIb trial, which is utilising SOZO® to measure fluid volume in patients with heart failure and chronic kidney disease, by 3 mont...read more

ImpediMed - Share Purchase Plan Offer Booklet (ASX:IPD)

You should read this Booklet in full. Eligible Shareholders have the opportunity to participate in the Share Purchase Plan offer by applying for up to $30,000 of new Shares without incurring brokera...read more

ImpediMed's Share Purchase Plan Opens (ASX:IPD)

The Share Purchase Plan (SPP) announced by ImpediMed Limited (ImpediMed or the Company) (ASX: IPD) on Wednesday, 27 October 2021 opens today. Eligible Shareholders in Australia and New Zealand now h...read more

ImpediMed - Appendix 4C & Quarterly Activities Report (ASX:IPD)

ImpediMed Limited (ASX.IPD) today released its Appendix 4C – Quarterly Cash Flow report for the period ended 30 September 2021. A summary of the quarterly results was released on 27 October 20...read more

ImpediMed Completes A$35 Million Institutional Placement (ASX:IPD)

ImpediMed Limited (ImpediMed or the Company) is pleased to announce that it has received firm commitments to raise A$35m (before costs) by the way of institutional placement to support product, data...read more

ImpediMed - Trading Halt (ASX:IPD)

The securities of Impedimed Limited (‘IPD’) will be placed in trading halt at the request of IPD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will ...read more

ImpediMed - PREVENT Trial Successful, Statistically Significant Results (ASX:IPD)

ImpediMed Limited (ASX.IPD) is pleased to announce the PREVENT Trial successfully met its primary endpoint. This study, which provides level I evidence, demonstrated that intervention in patients wi...read more

ImpediMed - Trading Halt (ASX:IPD)

ImpediMed - New Corporate Oncology Account with Icon Group (ASX:IPD)

ImpediMed Limited (ASX.IPD) is pleased to announce an agreement with Icon Group for the roll out of 13 SOZO units to establish lymphoedema screening services for breast cancer patients across Austra...read more

ImpediMed - SOZO Heart Failure Program Initiated at AdvocateAuroraHealth (ASX:IPD)

ImpediMed Limited (ASX.IPD) is pleased to announce the inaugural SOZO Heart Failure Program has been established at Advocate Health Care’s Heart Institute, Chicago Illinois under the guidance ...read more

ImpediMed - HFSA Abstracts Demonstrate Utility of SOZO for HF Patients (ASX:IPD)

ImpediMed Limited (ASX.IPD) today announced two abstracts are being presented in the poster session of the prestigious Heart Failure Society of America (HFSA) Annual Scientific Meeting September 10 ...read more

ImpediMed - Appendix 4G and Corporate Governance Statement (ASX:IPD)

ImpediMed Limited (ASX.IPD) is pleased to release its Appendix 4G and Corporate Governance Statement. Approved for release by the Board of ImpediMed Limited. For more information, download the...read more

ImpediMed - Annual Report 30 June 2021 (ASX:IPD)

ImpediMed Limited (ASX.IPD) is pleased to release its Annual Report for the year ended 30 June 2021. Approved for release by the Board of ImpediMed Limited. For more information, download the ...read more

ImpediMed - Appendix 4E (ASX:IPD)

ImpediMed Limited (ASX.IPD) today released its Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2021 (FY’21). Revenue Summary: SOZO Revenue grew by 64% ...read more

ImpediMed - Receipt of $1.8 Million R&D Tax Incentive Refund (ASX:IPD)

ImpediMed Limited (ASX.IPD) today announced the receipt of a $1.8 million cash refund related to the R&D Tax Incentive. The cash rebate is related to expenditure on eligible Australian and in...read more

Viewing: 16 - 30 of 32 Previous | Next